

Stanford



Philip Grant

Clinical Associate Professor, Medicine - Infectious Diseases

CLINICAL OFFICE (PRIMARY)

- **Division of Infectious Diseases**

300 Pasteur Dr Rm S169

Grant Bldg MC 5107

Stanford, CA 94305

Tel (650) 723-7912 **Fax** (650) 723-3474

Bio

BIO

My research focuses on antiretroviral therapy and complications of HIV including immune reconstitution inflammatory disease, osteoporosis, and cardiovascular disease.

CLINICAL FOCUS

- Infectious Disease

ACADEMIC APPOINTMENTS

- Clinical Associate Professor, Medicine - Infectious Diseases

PROFESSIONAL EDUCATION

- Board Certification: Infectious Disease, American Board of Internal Medicine (2024)
- Residency: University of Washington Medical Center Dept of Medicine (2003) WA
- Internship: University of Washington Medical Center Dept of Medicine (2001) WA
- Medical Education: University of California at San Francisco School of Medicine (2000) CA
- Fellowship, Stanford University Infectious Diseases (2010)

Research & Scholarship

CLINICAL TRIALS

- A Study of Ad26.COVS.2.S for the Prevention of SARS-CoV-2-Mediated COVID-19 in Adult Participants, Not Recruiting
- A Study to Treat Subjects With Telaprevir, Ribavirin, and Peginterferon Who Are Coinfected With HIV and Hepatitis C Virus (HCV), Not Recruiting
- D/C/F/TAF Versus COBI-boosted DRV Plus FTC/TDF in HIV-1 Infected, Antiretroviral Treatment Naive Adults, Not Recruiting
- Effect of Reducing Nucleotide Exposure on Bone Health (ReNew), Not Recruiting
- Effects of Aging on Primary and Secondary Vaccine Responses, Not Recruiting

- Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults, Not Recruiting
- FTC/RPV/TDF on T-Cell Activation, CD4+ T-Cell Count, Inflammatory Biomarkers and Viral Reservoir, Not Recruiting
- Immune Modulators for Treating COVID-19, Not Recruiting
- Open-label Safety Study of E/C/F/TAF (Genvoya®) in HIV-1 Positive Patients With Mild to Moderate Renal Impairment, Not Recruiting
- Prospective Observational Epidemiologic Study of Maraviroc's Safety, Not Recruiting
- Response to Inactivated Influenza Vaccine in Lymph Tissue and Blood, Not Recruiting
- Safety and Efficacy of E/C/F/TAF (Genvoya®) Versus E/C/F/TDF (Stribild®) in HIV-1 Infected, Antiretroviral Treatment-Naive Adults, Not Recruiting
- Safety of EVG+RTV Administered With Other Antiretroviral Agents for the Treatment of HIV-1 Infection, Not Recruiting
- Stanford Universities: The Stanford HIV Aging Cohort, Not Recruiting
- Study to Evaluate the Safety and Efficacy of a Single Tablet Regimen of Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate Compared With a Single Tablet Regimen of Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naive Adults, Not Recruiting
- Study to Evaluate the Safety and Efficacy of E/C/F/TAF Versus E/C/F/TDF in HIV-1 Positive, Antiretroviral Treatment-Naive Adults, Not Recruiting
- The Effects of Attenuated Versus Inactivated Flu Vaccine in Twin Sets, Not Recruiting

Publications

PUBLICATIONS

- **Age-dependent cytokine surge in blood precedes cancer diagnosis.** *Proceedings of the National Academy of Sciences of the United States of America*
Chen, G., Mohsin, A., Zheng, H., Rosenberg-Hasson, Y., Padilla, C., Sarin, K. Y., Dekker, C. L., Grant, P., Maecker, H. T., Lu, Y., Furman, D., Shen-Orr, S., Khatri, et al
2025; 122 (12): e2420502122
- **Sex differences and immune correlates of Long Covid development, symptom persistence, and resolution.** *Science translational medicine*
Hamlin, R. E., Pienkos, S. M., Chan, L., Stabile, M. A., Pinedo, K., Rao, M., Grant, P., Bonilla, H., Holubar, M., Singh, U., Jacobson, K. B., Jagannathan, P., Maldonado, et al
2024; 16 (773): eadr1032
- **Sex differences and immune correlates of Long COVID development, persistence, and resolution.** *bioRxiv : the preprint server for biology*
Hamlin, R. E., Pienkos, S. M., Chan, L., Stabile, M. A., Pinedo, K., Rao, M., Grant, P., Bonilla, H., Holubar, M., Singh, U., Jacobson, K. B., Jagannathan, P., Maldonado, et al
2024
- **Prevalence of Emergent Dolutegravir Resistance Mutations in People Living with HIV: A Rapid Scoping Review.** *Viruses*
Chu, C., Tao, K., Kouamou, V., Avalos, A., Scott, J., Grant, P. M., Rhee, S. Y., McCluskey, S. M., Jordan, M. R., Morgan, R. L., Shafer, R. W.
2024; 16 (3)
- **Associations between county-level public health expenditures and community health planning activities with COVID-19 incidence and mortality.** *Preventive medicine reports*
Liang, R., Kiang, M. V., Grant, P., Jackson, C., Rehkopf, D. H.
2023; 36: 102410
- **Safety and efficacy of sofosbuvir-velpatasvir to treat chronic hepatitis C virus infection in treatment-naive patients in Rwanda (SHARED-3): a single-arm trial.** *The lancet. Gastroenterology & hepatology*
Kateera, F., Shumbusho, F., Manirambona, L., Kabihizi, J., Murangwa, A., Serumondo, J., Makuza, J. D., Nsanzimana, S., Muvunyi, C. M., Kabakambira, J. D., Sylvain, H., Camus, G., Grant, et al
2022
- **Safety and efficacy of sofosbuvir-velpatasvir-voxilaprevir for re-treatment of chronic hepatitis C virus infection in patients with previous direct-acting antiviral treatment failure in Rwanda (SHARED-3): a single-arm trial.** *The lancet. Gastroenterology & hepatology*
Gupta, N., Manirambona, L., Shumbusho, F., Kabihizi, J., Murangwa, A., Serumondo, J., Makuza, J. D., Nsanzimana, S., Muvunyi, C. M., Mukabatsinda, C., Musabeyezu, E., Camus, G., Grant, et al
2022

- **Fostemsavir: a first-in-class HIV-1 attachment inhibitor.** *Current opinion in HIV and AIDS*
Grant, P. M., Kozal, M. J.
2022; 17 (1): 32-35
- **Survivors of SARS-CoV-2 Infection Show Neuropsychiatric Sequelae Measured by Surveys, Neurocognitive Testing, and Magnetic Resonance Imaging: Preliminary Results**
Hack, L., Brawer, J., Zhang, X., Wintermark, M., Jiang, B., Stetz, P., Yesavage, J., Grant, P., Bonilla, H., Subramanian, A., Williams, L.
SPRINGER NATURE.2021: 205-206
- **Factors Associated with Resilience Among Older People Living with HIV.** *AIDS and behavior*
Berko, J., Mazonson, P., Loo, T., Grant, P., Zolopa, A., Spinelli, F., Short, D.
2021
- **Patients with uncomplicated COVID-19 have long-term persistent symptoms and functional impairment similar to patients with severe COVID-19: a cautionary tale during a global pandemic.** *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America*
Jacobson, K. B., Rao, M., Bonilla, H., Subramanian, A., Hack, I., Madrigal, M., Singh, U., Jagannathan, P., Grant, P.
2021
- **Risk factors for difficult-to-treat Hepatitis C Virus genotype 4r in Rwanda and implications for elimination in sub-Saharan africa.** *Journal of viral hepatitis*
Shumbusho, F. n., Liu, A. F., Kateera, F. n., Kabahizi, J. n., Nsanzaimana, S. n., Serumondo, J. n., Damascene Makuza, J. n., Grant, P. M., Musabeyezu, E. n., Muvunyi, C. n., Gupta, N. n.
2021
- **SARS-CoV-2 Neutralization Resistance Mutations in Patient with HIV/AIDS, California, USA.** *Emerging infectious diseases*
Hoffman, S. A., Costales, C., Sahoo, M. K., Palanisamy, S., Yamamoto, F., Huang, C., Verghese, M., Solis, D. C., Sibai, M., Subramanian, A., Tompkins, L. S., Grant, P., Shafer, et al
2021; 27 (10)
- **Signatures of immune dysfunction in HIV and HCV infection share features with chronic inflammation in aging and persist after viral reduction or elimination.** *Proceedings of the National Academy of Sciences of the United States of America*
Lopez Angel, C. J., Pham, E. A., Du, H. n., Vallania, F. n., Fram, B. J., Perez, K. n., Nguyen, T. n., Rosenberg-Hasson, Y. n., Ahmed, A. n., Dekker, C. L., Grant, P. M., Khatri, P. n., Maecker, et al
2021; 118 (14)
- **Use of Remdesivir for Pregnant Patients with Severe Novel 2019 Coronavirus Disease.** *American journal of obstetrics and gynecology*
Igbino, I., Miller, S., Bianco, K., Nelson, J., Kappagoda, S., Blackburn, B. G., Grant, P., Subramanian, A., Lyell, D., El-Sayed, Y., Aziz, N.
2020
- **Cytokine profile in plasma of severe COVID-19 does not differ from ARDS and sepsis.** *JCI insight*
Wilson, J. G., Simpson, L. J., Ferreira, A., Rustagi, A., Roque, J. A., Asuni, A., Ranganath, T., Grant, P. M., Subramanian, A. K., Rosenberg-Hasson, Y., Maecker, H., Holmes, S., Levitt, et al
2020
- **A single-cell atlas of the peripheral immune response in patients with severe COVID-19.** *Nature medicine*
Wilk, A. J., Rustagi, A., Zhao, N. Q., Roque, J., Martinez-Colon, G. J., McKechnie, J. L., Ivison, G. T., Ranganath, T., Vergara, R., Hollis, T., Simpson, L. J., Grant, P., Subramanian, et al
2020
- **A single-cell atlas of the peripheral immune response to severe COVID-19.** *medRxiv : the preprint server for health sciences*
Wilk, A. J., Rustagi, A., Zhao, N. Q., Roque, J., Martinez-Colon, G. J., McKechnie, J. L., Ivison, G. T., Ranganath, T., Vergara, R., Hollis, T., Simpson, L. J., Grant, P., Subramanian, et al
2020
- **Enhancing natural killer cell function with gp41-targeting bispecific antibodies to combat HIV infection.** *AIDS (London, England)*
Ramadoss, N. S., Zhao, N. Q., Richardson, B. A., Grant, P. M., Kim, P. S., Blish, C. A.
2020
- **Safety and Efficacy of Limited Laboratory Monitoring for Hepatitis C Treatment: A Blinded Clinical Trial in Rwanda.** *Hepatology communications*

Grant, P., Shumbusho, F., Van Nuil, J. I., Kateera, F., Mukherjee, J., Kabahizi, J., Ntaganda, F., Nsanzimana, S., Mbituyumuremyi, A., Damascene, M. J., Muvunyi, C. M., Mukabatsinda, C., Musabeyezu, et al
2020; 4 (4): 569-576

- **Safety and Efficacy of Limited Laboratory Monitoring for Hepatitis C Treatment: A Blinded Clinical Trial in Rwanda** *HEPATOLOGY COMMUNICATIONS*
Grant, P., Shumbusho, F., Van Nuil, J., Kateera, F., Mukherjee, J., Kabahizi, J., Ntaganda, F., Nsanzimana, S., Mbituyumuremyi, A., Damascene, M., Muvunyi, C., Mukabatsinda, C., Musabeyezu, et al
2020
- **Remdesivir for 5 or 10 Days in Patients with Severe Covid-19.** *The New England journal of medicine*
Goldman, J. D., Lye, D. C., Hui, D. S., Marks, K. M., Bruno, R. n., Montejano, R. n., Spinner, C. D., Galli, M. n., Ahn, M. Y., Nahass, R. G., Chen, Y. S., SenGupta, D. n., Hyland, et al
2020
- **Improved quality of life following direct-acting antiviral treatment for chronic hepatitis C infection in Rwanda: Results from a clinical trial in sub-Saharan Africa (the SHARED study).** *Journal of viral hepatitis*
Van Nuil, J. I., Umutesi, G. n., Shumbusho, F. n., Kateera, F. n., Dushimimana, J. d., Muvunyi, C. M., Musabeyezu, E. n., Mukabatsinda, C. n., Ntirenganya, C. n., Kabahizi, J. n., Serumondo, J. n., Makuza, J. D., Nsanzimana, et al
2020
- **Treated HIV Infection Alters Phenotype but Not HIV-Specific Function of Peripheral Blood Natural Killer Cells.** *Frontiers in immunology*
Zhao, N. Q., Ferreira, A., Grant, P. M., Holmes, S., Blish, C. A.
2020; 11: 829
- **A systematic review of the genetic mechanisms of dolutegravir resistance.** *The Journal of antimicrobial chemotherapy*
Rhee, S. Y., Grant, P. M., Tzou, P. L., Barrow, G. n., Harrigan, P. R., Ioannidis, J. P., Shafer, R. W.
2019
- **Treatment of chronic hepatitis C virus infection in Rwanda with ledipasvir-sofosbuvir (SHARED): a single-arm trial.** *The lancet. Gastroenterology & hepatology*
Gupta, N., Mbituyumuremyi, A., Kabahizi, J., Ntaganda, F., Muvunyi, C. M., Shumbusho, F., Musabeyezu, E., Mukabatsinda, C., Ntirenganya, C., Van Nuil, J. I., Kateera, F., Camus, G., Damascene, et al
2018
- **Effect of Testosterone Use on Bone Mineral Density in HIV-Infected Men** *AIDS RESEARCH AND HUMAN RETROVIRUSES*
Grant, P. M., Li, X., Jacobson, L. P., Palella, F. J., Kingsley, L. A., Margolick, J. B., Dobs, A. S., Lake, J. E., Althoff, K. N., Brown, T. T.
2019; 35 (1): 75–80
- **Effect of Testosterone Use on Bone Mineral Density in HIV-infected Men.** *AIDS research and human retroviruses*
Grant, P. M., Li, X., Jacobson, L., Palella, F. J., Kingsley, L., Margolick, J. B., Dobs, A. S., Lake, J. E., Althoff, K. N., Brown, T.
2018
- **Safety and Efficacy of Ledipasvir/Sofosbuvir without on-Treatment Laboratory Monitoring in HCV-Infected Rwandans: The Shared 2 Study**
Grant, P., Kabahizi, J., Mbituyumuremyi, A., Van Nuil, J., Mukabatsinda, C., Damascene, M., Shumbusho, F., Ntirenganya, C., Nsanzimana, S., Gupta, N.
WILEY.2018: 36A
- **A Comparison of the Liver Fat Score and CT Liver-to-Spleen Ratio as Predictors of Fatty Liver Disease by HIV Serostatus.** *Journal of clinical gastroenterology and hepatology*
Mellor-Crummey, L. E., Lake, J. E., Wilhalme, H., Tseng, C., Grant, P. M., Erlandson, K. M., Price, J. C., Palella, F. J., Kingsley, L. A., Budoff, M., Post, W. S., Brown, T. T.
2018; 2 (3)
- **High Rates of Rapid Virologic Response for Chronic Hepatitis C Infection Treated with Ledipasvir/Sofosbuvir in Rwanda: Preliminary Results from the SHARED Study**
Gupta, N., Kabahizi, J., Muvunyi, C., Mbituyumuremyi, A., Van Nuil, J. I., Grant, P. M.
WILEY.2017: 615A
- **Collaborative update of a rule-based expert system for HIV-1 genotypic resistance test interpretation.** *PLoS one*
Paredes, R. n., Tzou, P. L., van Zyl, G. n., Barrow, G. n., Camacho, R. n., Carmona, S. n., Grant, P. M., Gupta, R. K., Hamers, R. L., Harrigan, P. R., Jordan, M. R., Kantor, R. n., Katzenstein, et al

2017; 12 (7): e0181357

- **Long-term body composition changes in antiretroviral-treated HIV-infected individuals** *AIDS*
Grant, P. M., Kitch, D., McComsey, G. A., Collier, A. C., Bartali, B., Koletar, S. L., Erlandson, K. M., Lake, J. E., Yin, M. T., Melbourne, K., Ha, B., Brown, T. T.
2016; 30 (18): 2805-2813
- **A Randomized Switch From Nevirapine-Based Antiretroviral Therapy to Single Tablet Rilpivirine/Emtricitabine/Tenofovir Disoproxil Fumarate in Virologically Suppressed Human Immunodeficiency Virus-1-Infected Rwandans.** *Open forum infectious diseases*
Collins, S. E., Grant, P. M., Uwinkindi, F., Talbot, A., Seruyange, E., Slamowitz, D., Mugeni, A., Remera, E., Niyonsenga, S. P., Nyirimigabo, J., Uwizihwe, J. P., Dongier, P., Muhayimpundu, et al
2016; 3 (3): ofw141-?
- **Long-term Bone Mineral Density Changes in Antiretroviral-Treated HIV-Infected Individuals** *JOURNAL OF INFECTIOUS DISEASES*
Grant, P. M., Kitch, D., McComsey, G. A., Collier, A. C., Koletar, S. L., Erlandson, K. M., Yin, M. T., Bartali, B., Ha, B., Melbourne, K., Brown, T. T.
2016; 214 (4): 607-611
- **Tenofovir and bone health** *CURRENT OPINION IN HIV AND AIDS*
Grant, P. M., Cotter, A. G.
2016; 11 (3): 326-332
- **Modifying Antiretroviral Therapy in Virologically Suppressed HIV-1-Infected Patients** *DRUGS*
Collins, S. E., Grant, P. M., Shafer, R. W.
2016; 76 (1): 75-98
- **Modifying Antiretroviral Therapy in Virologically Suppressed HIV-1-Infected Patients.** *Drugs*
Collins, S. E., Grant, P. M., Shafer, R. W.
2016; 76 (1): 75-98
- **Molecular Detection of Leptospira in Two Returned Travelers: Higher Bacterial Load in Cerebrospinal Fluid Versus Serum or Plasma.** *American journal of tropical medicine and hygiene*
Waggoner, J. J., Soda, E. A., Seibert, R., Grant, P., Pinsky, B. A.
2015; 93 (2): 238-240
- **Case Report: Molecular Detection of Leptospira in Two Returned Travelers: Higher Bacterial Load in Cerebrospinal Fluid versus Serum or Plasma** *AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE*
Waggoner, J. J., Soda, E. A., Seibert, R., Grant, P., Pinsky, B. A.
2015; 93 (2): 238-240
- **Clinically Indicated Corticosteroids Do Not Affect Bone Turnover During Immune Restoration of Severely Lymphopenic HIV-Infected Patients** *AIDS RESEARCH AND HUMAN RETROVIRUSES*
Grant, P. M., Sheikh, V., DerSimonian, R., Rupert, A., Roby, G., Pau, A., Sneller, M. C., Rico, S., Brown, T. T., Sereti, I.
2015; 31 (7): 739-744
- **Patterns of peripheral neuropathy in ART-na < ve patients initiating modern ART regimen** *JOURNAL OF NEUROVIROLOGY*
Lee, A. J., Bosch, R. J., Evans, S. R., Wu, K., Harrison, T., Grant, P., Clifford, D. B.
2015; 21 (2): 210-218
- **Differential skeletal impact of tenofovir disoproxil fumarate in young versus old HIV-infected adults** *HIV CLINICAL TRIALS*
Grant, P. M., Kitch, D., McComsey, G. A., Tierney, C., Ha, B., Brown, T. T.
2015; 16 (2): 66-71
- **Encephalitis caused by chikungunya virus in a traveler from the kingdom of tonga.** *Journal of clinical microbiology*
Nelson, J., Waggoner, J. J., Sahoo, M. K., Grant, P. M., Pinsky, B. A.
2014; 52 (9): 3459-3461
- **Association between Latent Proviral Characteristics and Immune Activation in Antiretrovirus-Treated Human Immunodeficiency Virus Type 1-Infected Adults.** *Journal of virology*
Liang, E. C., Sceats, L., Bayless, N. L., Strauss-Albee, D. M., Kubo, J., Grant, P. M., Furman, D., Desai, M., Katzenstein, D. A., Davis, M. M., Zolopa, A. R., Blish, C. A.
2014; 88 (15): 8629-8639

- **Clinical and Immunologic Predictors of Death After an Acute Opportunistic Infection: Results from ACTG A5164** *HIV CLINICAL TRIALS*
Grant, P. M., Komarow, L., Sanchez, A., Sattler, F. R., Asmuth, D. M., Pollard, R. B., Zolopa, A. R.
2014; 15 (4): 133-139
- **Evolution of HIV treatment guidelines in high- and low-income countries: Converging recommendations** *ANTIVIRAL RESEARCH*
Richardson, E. T., Grant, P. M., Zolopa, A. R.
2014; 103: 88-93
- **Comparative effectiveness and cost-effectiveness of antiretroviral therapy and pre-exposure prophylaxis for HIV prevention in South Africa.** *BMC medicine*
Alistar, S. S., Grant, P. M., Bendavid, E.
2014; 12: 46-?
- **Comparative effectiveness and cost-effectiveness of antiretroviral therapy and pre-exposure prophylaxis for HIV prevention in South Africa.** *BMC medicine*
Alistar, S. S., Grant, P. M., Bendavid, E.
2014; 12: 46-?
- **TREATING PSYCHOLOGICAL TRAUMA AMONG RWANDAN ORPHANS IS ASSOCIATED WITH A REDUCTION IN HIV RISK-TAKING BEHAVIORS: A PILOT STUDY** *AIDS EDUCATION AND PREVENTION*
Talbot, A., Uwihoreye, C., Kamen, C., Grant, P., McGlynn, L., Mugabe, I., Nshimyumukiza, M., Dongier, P., Slamowitz, D., Padilla, C., Uvamahoro, J., Musayidire, I., Mukarubuga, et al
2013; 25 (6): 468-479
- **Low Baseline CD4+ Count Is Associated With Greater Bone Mineral Density Loss After Antiretroviral Therapy Initiation.** *Clinical infectious diseases*
Grant, P. M., Kitch, D., McComsey, G. A., Dube, M. P., Haubrich, R., Huang, J., Riddler, S., Tebas, P., Zolopa, A. R., Collier, A. C., Brown, T. T.
2013; 57 (10): 1483-1488
- **Early Virologic Response to Abacavir/Lamivudine and Tenofovir/Emtricitabine During ACTG A5202** *HIV CLINICAL TRIALS*
Grant, P. M., Tierney, C., Budhathoki, C., Daar, E. S., Sax, P. E., Collier, A. C., Fischl, M. A., Zolopa, A. R., Balamane, M., Katzenstein, D.
2013; 14 (6): 284-291
- **Elevated Interleukin 8 and T-Helper 1 and T-Helper 17 Cytokine Levels Prior to Antiretroviral Therapy in Participants Who Developed Immune Reconstitution Inflammatory Syndrome During ACTG A5164** *JOURNAL OF INFECTIOUS DISEASES*
Grant, P. M., Komarow, L., Lederman, M. M., Pahwa, S., Zolopa, A. R., Andersen, J., Asmuth, D. M., Devaraj, S., Pollard, R. B., Richterman, A., Kanthikeel, S., Sereti, I.
2012; 206 (11): 1715-1723
- **When to start ART in the setting of acute AIDS-related opportunistic infections: the time is now!** *Current HIV/AIDS reports*
Grant, P. M., Zolopa, A. R.
2012; 9 (3): 251-258
- **When to Start ART in the Setting of Acute AIDS-Related Opportunistic Infections: The Time Is Now!** *CURRENT HIV/AIDS REPORTS*
Grant, P. M., Zolopa, A. R.
2012; 9 (3): 251-258
- **Blood (1 -> 3)-beta-D-Glucan as a Diagnostic Test for HIV-Related Pneumocystis jirovecii Pneumonia** *CLINICAL INFECTIOUS DISEASES*
Sax, P. E., Komarow, L., Finkelman, M. A., Grant, P. M., Andersen, J., Scully, E., Powderly, W. G., Zolopa, A. R.
2011; 53 (2): 197-202
- **Cost-effectiveness of antiretroviral regimens in the World Health Organization's treatment guidelines: a South African analysis** *AIDS*
Bendavid, E., Grant, P., Talbot, A., Owens, D. K., Zolopa, A.
2011; 25 (2): 211-220
- **Concerns Regarding a Randomized Study of the Timing of Antiretroviral Therapy in Zimbabweans with AIDS and Acute Cryptococcal Meningitis** *CLINICAL INFECTIOUS DISEASES*
Grant, P. M., Aberg, J. A., Zolopa, A. R.
2010; 51 (8): 984-985

- **Early Antiretroviral Therapy for Patients With Acute AIDS-Related Opportunistic Infections: A Cost-Effectiveness Analysis of ACTG A5164** *HIV CLINICAL TRIALS*
Sax, P. E., Sloan, C. E., Schackman, B. R., Grant, P. M., Rong, J., Zolopa, A. R., Powderly, W., Losina, E., Freedberg, K. A.
2010; 11 (5): 248-259
- **Optimal antiretroviral therapy: HIV-1 treatment strategies to avoid and overcome drug resistance** *CURRENT OPINION IN INVESTIGATIONAL DRUGS*
Grant, P. M., Zolopa, A. R.
2010; 11 (8): 901-910
- **Risk Factor Analyses for Immune Reconstitution Inflammatory Syndrome in a Randomized Study of Early vs. Deferred ART during an Opportunistic Infection** *PLOS ONE*
Grant, P. M., Komarow, L., Andersen, J., Sereti, I., Pahwa, S., Lederman, M. M., Eron, J., Sanne, I., Powderly, W., Hogg, E., Suckow, C., Zolopa, A.
2010; 5 (7)
- **Predicting Tipranavir and Darunavir Resistance Using Genotypic, Phenotypic, and Virtual Phenotypic Resistance Patterns: an Independent Cohort Analysis of Clinical Isolates Highly Resistant to All Other Protease Inhibitors** *ANTIMICROBIAL AGENTS AND CHEMOTHERAPY*
Talbot, A., Grant, P., Taylor, J., Baril, J., Liu, T. F., Charest, H., Brenner, B., Roger, M., Shafer, R., Cantin, R., Zolopa, A.
2010; 54 (6): 2473-2479
- **International Cohort Analysis of the Antiviral Activities of Zidovudine and Tenofovir in the Presence of the K65R Mutation in Reverse Transcriptase** *ANTIMICROBIAL AGENTS AND CHEMOTHERAPY*
Grant, P. M., Taylor, J., Nevins, A. B., Calvez, V., Marcelin, A., Wirden, M., Zolopa, A. R.
2010; 54 (4): 1520-1525
- **Switch from enfuvirtide to raltegravir in virologically suppressed HIV-1 infected patients: Effects on level of residual viremia and quality of life** *JOURNAL OF CLINICAL VIROLOGY*
Grant, P. M., Palmer, S., Bendavid, E., Talbot, A., Slamowitz, D. C., Cain, P., Kobayashi, S. S., Balamane, M., Zolopa, A. R.
2009; 46 (4): 305-308
- **The use of resistance testing in the management of HIV-1-infected patients** *CURRENT OPINION IN HIV AND AIDS*
Grant, P. M., Zolopa, A. R.
2009; 4 (6): 474-480
- **Initiation of antiretroviral therapy in the hospitalized patient with an acute AIDS-related opportunistic infection and other conditions: no time to lose.** *Current HIV/AIDS reports*
Grant, P., Zolopa, A.
2009; 6 (2): 63-67
- **Maintaining Reduced Viral Fitness and CD4 Response in HIV-Infected Patients with Viremia Receiving a Boosted Protease Inhibitor** *CLINICAL INFECTIOUS DISEASES*
Grant, P., Taylor, J., Cain, P., Short, W., Gallant, J., Farthing, C., Thal, G., Coakley, E., Zolopa, A.
2009; 48 (5): 680-682
- **Virologic Response to Lopinavir-Ritonavir-Based Antiretroviral Regimens in a Multicenter International Clinical Cohort: Comparison of Genotypic Interpretation Scores** *ANTIMICROBIAL AGENTS AND CHEMOTHERAPY*
Grant, P., Wong, E. C., Rode, R., Shafer, R., De Luca, A., Nadler, J., Hawkins, T., Cohen, C., Harrington, R., Kempf, D., Zolopa, A.
2008; 52 (11): 4050-4056
- **Integrase inhibitors: a clinical review of raltegravir and elvitegravir.** *Journal of HIV therapy*
Grant, P., Zolopa, A.
2008; 13 (2): 36-39